Microbot Medical has taken a big step forward with the FDA’s clearance of its LIBERTY Endovascular Robotic System. This innovative device aims to change how doctors perform peripheral blood vessel procedures by offering a single-use, remotely operated robot. It promises to make procedures safer, more efficient, and less taxing for healthcare providers.

Revolutionizing Endovascular Procedures

The LIBERTY system is designed specifically for peripheral endovascular treatments. It allows physicians to navigate blood vessels remotely, reducing the physical strain and exposure to radiation during procedures. In a key study, the system achieved a 100% success rate in guiding the robot to the target area, with no device-related adverse events reported. It also cut physicians’ radiation exposure by 92%, which could lead to better ergonomics and less fatigue for medical staff.

This technology is set to streamline procedures, potentially lowering costs and improving outcomes for patients. The system’s ease of use and safety profile could make it a new standard in vascular interventions, especially as the company prepares to bring it to market.

Plans for Market Launch and Growth

With FDA clearance secured, Microbot Medical is now focusing on launching the LIBERTY system commercially. The company aims to tap into the roughly 2.5 million peripheral vascular procedures performed annually in the U.S. alone and expand into international markets. They believe that the system’s ability to boost procedure efficiency and safety will resonate with hospitals and clinics worldwide.

Microbot has been developing its commercial strategy since early this year, positioning itself to move quickly once marketing approval is finalized. The company envisions the LIBERTY system not only improving clinical outcomes but also reducing costs, making advanced robotic care more accessible. This milestone validates their mission to expand access to robotic technology in healthcare and address unmet needs in minimally invasive treatments.

Upcoming Events and Investor Opportunities

Microbot Medical’s leadership team will present at the H.C. Wainwright Annual Investor Conference on September 9, 2025, at 9:00 am ET. Interested investors can watch the live webcast or contact the company’s representatives for one-on-one meetings. This presentation offers an opportunity to learn more about the company’s vision and the potential impact of the LIBERTY system.

The company is committed to ongoing clinical data collection even as it begins commercial sales. With FDA clearance in hand, Microbot is ready to advance its robotic platform and make a significant contribution to endovascular care. The LIBERTY system’s unique design and proven safety profile position it as a game-changer in the field, promising to improve safety, reduce radiation risk, and enhance procedural efficiency for healthcare providers around the world.

Inspired by

• https://ai-techpark.com/microbot-medical-gets-fda-clearance-for-liberty-robot/